SALADINI FRANCESCO

Francesco
Saladini
Ricercatore Legge 240/10 - tempo determinato

Contacts

0577235077 [int.5077]

Teaching activities

Completion accademic year: 2024/2025

Course year: 1 Second cycle degree (Laurea Magistrale) MEDICAL BIOTECHNOLOGIES A.Y. 2024/2025

Completion accademic year: 2023/2024

Course year: 2 CHIRURGIA ORALE A.Y. 2022/2023

Completion accademic year: 2022/2023

Course year: 2 CHIRURGIA ORALE A.Y. 2021/2022

Completion accademic year: 2021/2022

Course year: 1 First cycle degree (DM 270) DIETISTIC A.Y. 2021/2022

Completion accademic year: 2020/2021

Course year: 1 First cycle degree (DM 270) DIETISTIC A.Y. 2020/2021
Course year: 1 First cycle degree (DM 270) BIOMEDICAL LABORATORY TECHNIQUES A.Y. 2020/2021

Completion accademic year: 2019/2020

Course year: 1 First cycle degree (DM 270) BIOMEDICAL LABORATORY TECHNIQUES A.Y. 2019/2020

Research

Ultime pubblicazioni:

  • Armenia, D., Carioti, L., Micheli, V., Bon, I., Allice, T., Bonura, C., et al. (2024). Comparison of Different HIV-1 Resistance Interpretation Tools for Next-Generation Sequencing in Italy. VIRUSES, 16(9) [10.3390/v16091422]. - view more
  • Giammarino, F., de Salazar, A., Malet, I., Vinuela, L., Fuentes, A., Saladini, F., et al. (2024). Prevalence and Phenotypic Susceptibility to Doravirine of the HIV-1 Reverse Transcriptase V106I Polymorphism in B and Non-B Subtypes. THE JOURNAL OF INFECTIOUS DISEASES, 229(6), 1796-1802 [10.1093/infdis/jiae010]. - view more
  • Mazzitelli, M., Pontillo, D., Clemente, T., Di Biagio, A., Cenderello, G., Rusconi, S., et al. (2024). Polypharmacy, anticholinergic burden and drug-drug interaction assessment in people with four-class-resistant HIV: data from the PRESTIGIO registry. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 79(9), 2163-2169 [10.1093/jac/dkae190]. - view more
  • Panza, F., Saladini, F., Bartolini, N., Gianmarino, F., Montagnani, F., Spagnuolo, V., et al. (2024). PRESTIGIO RING “a 59-year-old man with multidrug resistant HIV-1 infection failing a regimen including dolutegravir, rilpivirine, atazanavir/cobicistat: successful treatment tailoring based on genotypic and phenotypic resistance tests”. NEW MICROBIOLOGICA, 47(1), 116-122. - view more
  • Fiaschi, L., Biba, C., Varasi, I., Bartolini, N., Paletti, C., Giammarino, F., et al. (2024). In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants. VIRUSES, 16(2), 1-12 [10.3390/v16020168]. - view more